Investor Presentation H1 2023
69
Investor presentation
First six months of 2023
In STEP 5, people treated with semaglutide 2.4 mg sustained
their weight loss over 2 years
% change in body weight
Clinically relevant and sustained weight loss in patients
with obesity or overweight
0 2 4 6∞
-2
-10
-12
-14
-16
-18
-20
Data from STEP 5
Placebo: -0.6%
40% of patients lost ≥ 20% of their body
weight
Semaglutide 2.4 mg: -16.7%
0 8 16 24 32 40 48 56 64 72 80 88 96 104
Time since initiation (weeks)
Change in body weight in % depicts observed means since time of randomisation; trial product estimand; mean body weight: 106.0 kg
Semaglutide appeared to have a safe
and well-tolerated profile
Improvements in lipid profiles as well as C-
reactive protein
Novo NordiskⓇView entire presentation